Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Health related quality of life among patients with chronic graft-versus-host disease in China.

Mo XD, Xu LP, Liu DH, Chen YH, Zhang XH, Chen H, Han W, Wang Y, Wang FR, Wang JZ, Liu KY, Huang XJ.

Chin Med J (Engl). 2013 Aug;126(16):3048-52.

PMID:
23981610
2.

Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT.

Mo XD, Xu LP, Liu DH, Chen YH, Han W, Zhang XH, Chen H, Wang Y, Wang JZ, Liu KY, Huang XJ.

Bone Marrow Transplant. 2012 Sep;47(9):1201-5. doi: 10.1038/bmt.2011.250. Epub 2012 Jan 9.

PMID:
22231459
3.

Impact of ocular graft-versus-host disease on visual quality of life in patients after allogeneic stem cell transplantation: questionnaire study.

Riemens A, Te Boome LC, Kalinina Ayuso V, Kuiper JJ, Imhof SM, Lokhorst HM, Aniki R.

Acta Ophthalmol. 2014 Feb;92(1):82-7. doi: 10.1111/aos.12047. Epub 2013 Apr 22.

4.

Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringdén O.

Biol Blood Marrow Transplant. 2002;8(12):674-82.

PMID:
12523580
5.

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.

MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM, Blazar BR.

Biol Blood Marrow Transplant. 2002;8(7):387-94.

PMID:
12171485
6.

Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation.

Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R, Dawood Markous RS, Collins GS, Ciceri F, Mandelli F, Marktel S, La Nasa G.

Biol Blood Marrow Transplant. 2011 Jun;17(6):861-6. doi: 10.1016/j.bbmt.2010.09.011. Epub 2010 Sep 24.

7.

Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia.

La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, Sanna M, Marcias M, Littera R, Carcassi C, Lucarelli G.

Blood. 2013 Sep 26;122(13):2262-70. doi: 10.1182/blood-2013-05-502658. Epub 2013 Aug 19.

8.

[Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].

Liu QF, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.

Ai Zheng. 2004 Apr;23(4):426-9. Chinese.

PMID:
15087032
9.
10.

Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1341-8. doi: 10.1016/j.bbmt.2014.05.001. Epub 2014 May 9.

11.

Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.

Rupa-Matysek J, Lewandowski K, Nowak W, Sawiński K, Gil L, Komarnicki M.

Transplant Proc. 2011 Jun;43(5):1915-23. doi: 10.1016/j.transproceed.2011.02.011.

PMID:
21693300
12.
13.

One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, Fenu S, Moleti ML, De Felice L, Girelli G, Arcese W.

Haematologica. 2003 Mar;88(3):315-23.

14.

Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.

Fraile P, Vazquez L, Caballero D, Garcia-Cosmes P, López L, San Miguel J, Tabernero JM.

Eur J Haematol. 2013 Aug;91(2):129-34. doi: 10.1111/ejh.12149. Epub 2013 Jun 28. Erratum in: Eur J Haematol. 2013 Oct;91(4):380. Pilar, Fraile [corrected to Fraile, Pilar]; Lourdes, Vazquez [corrected to Vazquez, Lourdes]; Dolores, Caballero [corrected to Caballero, Dolores]; Pedro, Garcia-Cosmes [corrected to Garcia-Cosmes, Pedro]; Lucia, López [corrected to López, Lucia]; Jesus, San Miguel [corrected to San Miguel, Jesus]; Jose Matias, Tabernero [corrected to Tabernero, Jose Matias].

PMID:
23710658
15.

Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kondo T, Yamashita K, Ichinohe T, Ishikawa T, Kadowaki N, Takaori-Kondo A.

Int J Hematol. 2013 Jan;97(1):109-16. doi: 10.1007/s12185-012-1229-0. Epub 2012 Dec 7.

PMID:
23225486
17.

[Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].

Liu QF, Fan ZP, Sun J, Zhang Y, Liu XL, Xu D, Xu B, Feng R, Meng FY, Zhou SY.

Di Yi Jun Yi Da Xue Xue Bao. 2004 Nov;24(11):1227-9, 1241. Chinese.

18.

Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease.

Aisa Y, Mori T, Kato J, Yamane A, Kohashi S, Kikuchi T, Okamoto S.

Int J Hematol. 2013 Feb;97(2):263-71. doi: 10.1007/s12185-013-1268-1. Epub 2013 Feb 1.

PMID:
23371545
19.

Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ.

Biol Blood Marrow Transplant. 2013 Jun;19(6):967-72. doi: 10.1016/j.bbmt.2013.03.014. Epub 2013 Mar 27.

20.

Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

Lee Sk, Cook EF, Soiffer R, Antin JH.

Biol Blood Marrow Transplant. 2002;8(8):444-52.

PMID:
12234170

Supplemental Content

Support Center